A hypoxia related long non-coding RNA signature could accurately predict survival outcomes in patients with bladder cancer

Abstract

Hypoxia plays a significant role in tumor progression. This study aimed to develop a hypoxiarelated long noncoding RNA (lncRNA) signature for predicting survival outcomes of patients with bladder cancer (BC). The transcriptome and clinicopathologic data were downloaded from The Cancer Genome Atlas (TCGA) database. Univariate Cox regression analysis and Lasso regression analysis were used to screened lncRNAs. Ten lncRNAs were screened out and included into the hypoxia lncRNA signature. The risk score based on hypoxia lncRNA signature could accurately predict the survival outcomes of BC patients. Immune infiltration analysis showed that six types of immune cells had significant different infiltration. Tumor mutation burden (TMB) analysis showed that the risk scores between the wild types and the mutation types of TP53, FGFR3, and RB1 were significantly different. Gene Set Enrichment Analysis (GSEA) showed that cancer-associated pathways belonged to the high risk groups and immune-related signal pathways were enriched into the low risk group. Then, we constructed a predictive model with the risk score, age, and clinical stage, which showed a robust prognostic performance. An lncRNA-mRNA coexpression network was constructed, which contained 62 lncRNA-mRNA links among 10 lncRNAs and 40 related mRNAs. In summary, the hypoxia lncRNA signature could accurately predict prognosis, chemotherapy and immunotherapy response in patients with BC and was relevant to clinicopathologic parameters and immune cell infiltration.

An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer

“…Although minimally invasive technology, enhanced endoscopy with narrow-band, neoadjuvant chemotherapy, targeted therapy, and immunotherapy have been introduced into clinical practice in recent years, the 5 years survival rates of BC patients have not improved in the past 30 years ( Berdik, 2017 ; Grayson, 2017 ). Moreover, to predict BC patients’ survival accurately, the AJCC-stage system based on classical pathological parameters also needs to improve ( Sun et al, 2020 ; Zhang et al, 2021a ). Therefore, with the widespread application of next generation sequencing (NGS), an increasing number of studies have focused on biomarkers and molecular subtypes of cancers to provide a theoretical basis for the development of new targeted drugs or to more accurately predict the prognosis of patients ( Zhang et al, 2021b ).…”

Constructing an immune‐ and ferroptosis‐related lncRNA signature to predict the immune landscape of human bladder cancer

“…Recently, to assess the prognosis of patients with tumors, researchers have focused on establishing signatures based on coding genes, non‐coding RNAs, and non‐coding RNA pairs, 25 , 26 , 27 , 28 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 most of which are based on the quantification of gene expression levels. Moreover, most of them were associated with either immune‐related or ferroptosis‐related RNAs.…”

A Necroptosis-Related lncRNA to Develop a Signature to Predict the Outcome, Immune Landscape, and Chemotherapeutic Responses in Bladder Urothelial Carcinoma

“…Many studies linked necroptosis to cancer incidence, progression, and metastasis (37,38). Necroptosis is also a viable strategy for eliminating cancer cells (39).…”

“…Zhang et al evaluated the expression levels of ten hypoxiarelated lncRNAs to establish a signature predicting survival in BLCA (39). However, there is currently no study of nrlncRNAs in BLCA.…”